85 related articles for article (PubMed ID: 7191272)
1. Inhibition of prolactin secretion in rats with the ergoline derivative deprenon.
Chlebounová J; Seda M; Fingerová H; Rezábek K
Arzneimittelforschung; 1980; 30(6):956-8. PubMed ID: 7191272
[TBL] [Abstract][Full Text] [Related]
2. Effect of d-6-methyl-8-ergoline-i-ylacetamide (Deprenon) on the FSH content of the pituitary in castrated female rats.
Rezábek K; Recábek K
Physiol Bohemoslov; 1976; 25(5):407-10. PubMed ID: 136001
[TBL] [Abstract][Full Text] [Related]
3. Interaction of perphenazine and an ergoline derivative on oestrogen-induced adenohypophyseal growth.
Schreiber V; Pribyl T
Physiol Bohemoslov; 1977; 26(1):31-8. PubMed ID: 140398
[TBL] [Abstract][Full Text] [Related]
4. Interactions between estrogens, prolactin, and growth hormone on the growth of N-nitrosomethylurea-induced rat mammary tumors.
Rose DP; Gottardis M
Anticancer Res; 1985; 5(4):397-402. PubMed ID: 4037735
[TBL] [Abstract][Full Text] [Related]
5. Effect of D-6-methyl-8-ergoline-I-ylacetamide (Deprenon) on the FSH content of the rat pituitary during the oestrus cycle and pregnancy.
Chlebounová J; Rezábek K; Seda M; Semonský M
Physiol Bohemoslov; 1974; 23(2):113-8. PubMed ID: 4280585
[No Abstract] [Full Text] [Related]
6. Effect of ergoline derivative VUFB-6638 on the adenohypophysial prolactin concentration in rats.
Krejcí P; Ausková M; Rezábek K; Bílek J; Semonský M
Endocrinol Exp; 1975 Jan; 9(1):68-72. PubMed ID: 6259
[TBL] [Abstract][Full Text] [Related]
7. Diminution of prostate by ergoline derivative VUFB--6638 (Dironyl) in rats.
Ausková M; Rezábek K; Marhan O; Zikán V; Semonský M
Endocrinol Exp; 1979 Sep; 13(3):171-6. PubMed ID: 315868
[TBL] [Abstract][Full Text] [Related]
8. Inhibition by an ergoline derivative (dopaminergic agonist) of oestradiol-induced adenohypophyseal growth and of the decrease in the hypothalamic ascorbic acid (HAA) concentration in rats.
Schreiber V; Pribyl T; Jahodová J
Physiol Bohemoslov; 1982; 31(2):97-100. PubMed ID: 6212960
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of prolactin secretion by ergolines.
Clemens JA; Shaar CJ; Smalstig EB; Bach NJ; Kornfeld EC
Endocrinology; 1974 Apr; 94(4):1171-6. PubMed ID: 4818776
[No Abstract] [Full Text] [Related]
10. Estrogen modulates the action of nitric oxide in the medial preoptic area on luteinizing hormone and prolactin secretion.
Moreno AS; Franci CR
Life Sci; 2004 Mar; 74(16):2049-59. PubMed ID: 14967199
[TBL] [Abstract][Full Text] [Related]
11. Prolactin secretion inhibition by a new 8alpha-amino-ergoline, CH 29-171.
Flückiger E; Briner U; Doepfner W; Kovacs E; Marbach P; Wagner HR
Experientia; 1978 Oct; 34(10):1330-2. PubMed ID: 570121
[No Abstract] [Full Text] [Related]
12. Metabolite involvement in bromocriptine-induced prolactin inhibition in rats.
Valente D; Delaforge M; Urien S; Guivarc'h D; Vienet R; Grognet JM; Ezan E
J Pharmacol Exp Ther; 1997 Sep; 282(3):1418-24. PubMed ID: 9316855
[TBL] [Abstract][Full Text] [Related]
13. Effects of the cocaine- and amphetamine-regulated transcript peptide on the turnover of dopamine in tuberoinfundibular neurons and serum prolactin levels: studies using estrogen, melanin concentrating hormone, and melanocortin.
Yang SC; Shieh KR
Neuropharmacology; 2004 Dec; 47(7):1070-80. PubMed ID: 15555641
[TBL] [Abstract][Full Text] [Related]
14. Correlation between inhibitory effect on prolactin secretion and antitumor activity of new ergoline compounds on DMBA-induced tumors in rats.
Formelli F; Zaccheo T; Di Salle E; Ornati G; Di Marco A
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1545-51. PubMed ID: 6416848
[TBL] [Abstract][Full Text] [Related]
15. Reciprocal changes in prolactin and growth hormone secretion in vitro after in vivo estrogen treatment.
Horváth JE; Schally AV
Acta Biol Hung; 1994; 45(2-4):249-62. PubMed ID: 7725821
[TBL] [Abstract][Full Text] [Related]
16. [Effects of estrogen or reserpine on activation of the corpora lutea in intrasplenic ovarian transplants].
Maekawa K; Tsunenari Y; Akiyoshi T
Zasshi Tokyo Ika Daigaku; 1968 Jul; 26(3):513-7. PubMed ID: 5750358
[No Abstract] [Full Text] [Related]
17. Opioids and the pulsatile prolactin secretory pattern: effects of hyperprolactinemia.
Lafuente A; Marco J; Esquifino AI
Vet Hum Toxicol; 1994 Dec; 36(6):524-8. PubMed ID: 7900271
[TBL] [Abstract][Full Text] [Related]
18. Long-term dysregulation of circadian and 17-beta estradiol-induced LH, prolactin and corticosterone secretion after dimethylbenz (a) anthracene administration in the Sprague-Dawley female rat.
Yon de Jonage-Canonico MB; Lenoir V; Scholler R; Kerdelhué B
Breast Cancer Res Treat; 2005 Jul; 92(1):47-50. PubMed ID: 15980990
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid profiles in hepatic membranes of rats with different levels of circulating estrogen and prolactin.
Bellini MJ; Carino MH; Tacconi-Gómez Dumm N; Goya RG
Comp Biochem Physiol A Mol Integr Physiol; 2007 Apr; 146(4):470-4. PubMed ID: 16490375
[TBL] [Abstract][Full Text] [Related]
20. Interactions between hypothalamic and peripheral hormones in the control of prolactin secretion.
Ferland L; Labrie F; Kelly PA; Raymond V
Fed Proc; 1980 Sep; 39(11):2917-22. PubMed ID: 7409210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
